全球外阴阴道念珠菌病治疗市场研究报告 - 2023 年至 2030 年行业分析、规模、份额、增长、趋势和预测

预计到 2030 年，全球外阴阴道念珠菌病治疗市场的市场规模将从 2022 年的 42 亿美元达到近 69.6 亿美元，2023-2030 年研究期间复合年增长率为 6.51%。

外阴阴道念珠菌病治疗是针对阴道酵母菌感染（一种常见的真菌感染）的治疗。瘙痒、排尿或性交时有烧灼感或不适、肿胀、皮疹和炎症，都是阴道酵母菌感染的症状。随着糖尿病病例的增加和人们更频繁地使用抗生素，外阴阴道念珠菌病的患病率也在增加。通常建议使用抗真菌药物来治疗阴道念珠菌病。

市场动态：

随着外阴阴道念珠菌病感染的增加以及对治疗该病的有效药物的需求，预计市场将呈增长趋势。研究和开发、新药批准和产品上市的显着增加正在扩大对更好治疗选择的需求，为外阴阴道念珠菌病治疗的商业增长创造有利可图的机会。此外，由于医疗保健和政府投资的增加、医疗保健系统的发展、药物的可及性以及製药和生物技术领域的重大技术发展，在预期的时间内，外阴阴道念珠菌病的治疗将有很多机会部门。由于缺乏公众意识、缺乏采用新技术的专业知识以及与诊断和治疗方法相关的高成本，预计外阴阴道念珠菌病治疗市场将受到阻碍。

该研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具还对全球外阴阴道念珠菌病治疗市场的各个细分市场进行了包容性评估。外阴阴道念珠菌病治疗行业的增长和趋势为本研究提供了整体方法。

区域分析：

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲外阴阴道念珠菌病治疗市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。外阴阴道念珠菌病治疗市场的主要参与者包括Astellas Pharma Inc.、Mycovia Pharmaceuticals Inc.、Bayer AG.、Basilea Pharmaceutica Ltd.、Scynexis Inc.、Grupo Ferrer Internacional SA、Pfizer Inc.、Cadila Pharmaceuticals、Bristol-Myers Squibb Company 。本节包含竞争格局的整体视图，包括各种战略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何定制要求，请写信给我们。我们的研究团队可以根据您的需求提供定制报告。

目录

第一章：前言

• 报告说明
  • 客观的
  • 目标受众
  • 独特的销售主张 (USP) 和产品
• 研究范围
• 研究方法论
  • 市场研究过程
  • 市场研究方法论

第 2 章：执行摘要

• 市场亮点
• 全球市场概况

第 3 章：外阴阴道念珠菌病治疗 - 行业分析

• 简介 - 市场动态
• 市场驱动因素
• 市场限制
• 机会
• 行业动态
• 波特五力分析
• 市场吸引力分析
  • 按药品类别分類的市场吸引力分析
  • 按给药途径进行的市场吸引力分析
  • 按分销渠道分類的市场吸引力分析
  • 市场吸引力分析：按地区

第 4 章：价值链分析

• 价值链分析
• 原材料分析
  • 原材料清单
  • 原料厂商清单
  • 主要原材料价格走势
• 潜在买家名单
• 营销渠道
  • 直效行销
  • 间接营销
  • 营销渠道发展趋势

第 5 章：COVID-19 爆发的影响分析

• Covid-19 爆发的影响分析
  • 对生产的直接影响
  • 供应炼和市场颠覆
  • 对公司和金融市场的财务影响
• 按生产、进口、出口和需求分類的 COVID-19 影响分析
• 市场：COVID-19 前 V/S 后
• 冠状病毒 (COVID-19) 疫情的预计影响
• COVID-19：微观和宏观因素分析

第 6 章：全球外阴阴道念珠菌病治疗市场分析：按药物类别

• 按药物类别概述
• 历史和预测数据
• 按药物类别分析
• 克霉唑
• 制霉菌素
• 氟康唑
• 酮康唑
• 特比萘芬
• 特康唑
• 其他的

第 7 章：全球外阴阴道念珠菌病治疗市场分析：按给药途径

• 按给药途径概述
• 历史和预测数据
• 按给药途径分析
• 口服
• 静脉
• 专题

第 8 章：全球外阴阴道念珠菌病治疗市场销售分析：按分销渠道

• 按分销渠道分類的概览
• 历史和预测数据
• 按分销渠道分析
• 医院药房
• 零售药房
• 网上药房

第 9 章：全球外阴阴道念珠菌病治疗市场销售分析：按地理位置

• 区域展望销售分析
• 简介 销售分析
• 北美销售分析
  • 概述、历史和预测销售分析
  • 北美按细分市场销售分析
  • 北美按国家/地区销售分析
  • 美国销售分析
  • 加拿大销售分析
  • 墨西哥销售分析
• 欧洲销售分析
  • 概述、历史和预测销售分析
  • 欧洲按细分市场销售分析
  • 欧洲按国家/地区销售分析
  • 英国销售分析
  • 法国销售分析
  • 德国销售分析
  • 意大利销售分析
  • 俄罗斯销售分析
  • 欧洲其他地区销售分析
• 亚太地区销售分析
  • 概述、历史和预测销售分析
  • 亚太地区按细分市场销售分析
  • 亚太地区国家/地区销售分析
  • 中国销售分析
  • 印度销售分析
  • 日本销售分析
  • 韩国销售分析
  • 澳大利亚销售分析
  • 亚太地区其他地区销售分析
• 拉丁美洲销售分析
  • 概述、历史和预测销售分析
  • 拉丁美洲按细分市场销售分析
  • 拉丁美洲按国家/地区销售分析
  • 巴西销售分析
  • 阿根廷销售分析
  • 秘鲁销售分析
  • 智利销售分析
  • 拉丁美洲其他地区销售分析
• 中东和非洲销售分析
  • 概述、历史和预测销售分析
  • 中东和非洲按细分市场销售分析
  • 中东和非洲国家销售分析
  • 沙特阿拉伯销售分析
  • 阿联酋销售分析
  • 以色列销售分析
  • 南非销售分析
  • 中东其他地区和非洲销售分析

第 10 章：外阴阴道念珠菌病治疗公司的竞争格局

• 外阴阴道念珠菌病治疗市场竞争
• 伙伴关係/协作/协议
• 併购
• 新产品发布
• 其他发展

第 11 章：公司简介

• 十大公司股票分析
• 市场集中度
• Astellas Pharma Inc.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Mycovia Pharmaceuticals Inc.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Bayer AG.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Basilea Pharmaceutica Ltd.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Scynexis Inc.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Grupo Ferrer Internacional SA
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Pfizer Inc.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Cadila Pharmaceuticals
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Bristol-Myers Squibb Company
• 公司简介
• 公司收入
• 产品
• 最近的发展

注意 - 在公司概况中，财务详细信息和近期发展视情况而定，或者如果是私营公司，则可能不包括在内

The global demand for Vulvovaginal Candidiasis Treatment Market is presumed to reach the market size of nearly USD 6.96 BN by 2030 from USD 4.2 BN in 2022 with a CAGR of 6.51% under the study period 2023 - 2030.

Vulvovaginal candidiasis treatment is a treatment for vaginal yeast infection, a common fungus infection. Itching, a burning feeling or discomfort during urine or intercourse, swelling, rash, and inflammation, are all signs of vaginal yeast infection. As diabetic cases rise and people use antibiotics more frequently, vulvovaginal candidiasis prevalence has grown. Antifungal medicines are typically recommended for the treatment of vaginal candidiasis.

MARKET DYNAMICS:

The market is foreseen to follow a growing trend with the increase in vulvovaginal candidiasis infections and the requirement for effective medicines to treat the condition. The significant increase in research and development, new drug approvals, and product launches are scaling up the demand for better treatment options, creating a profitable opportunity for the commercial growth of vulvovaginal candidiasis treatment. In addition, there will be a lot of opportunities for the treatment of vulvovaginal candidiasis over the anticipated time frame because of an increase in healthcare and government investments, development of the healthcare system, accessibility of medications, and significant technological developments in the pharmaceutical and biotechnology sectors. The market for vulvovaginal candidiasis treatment is estimated to be hampered due to lack of public awareness, expertise in employing new technologies, and high costs related to diagnostic and treatment methods.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of vulvovaginal candidiasis treatment. The growth and trends of vulvovaginal candidiasis treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the vulvovaginal candidiasis treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

• Clotrimazole
• Nystatin
• Fluconazole
• Ketoconazole
• Terbinafine
• Terconazole
• Others

By Route Of Administration

• Oral
• Intravenous
• Topical

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Vulvovaginal Candidiasis Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the vulvovaginal candidiasis treatment market include Astellas Pharma Inc., Mycovia Pharmaceuticals Inc., Bayer AG., Basilea Pharmaceutica Ltd., Scynexis Inc., Grupo Ferrer Internacional S.A., Pfizer Inc., Cadila Pharmaceuticals, Bristol-Myers Squibb Company. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . VULVOVAGINAL CANDIDIASIS TREATMENT - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Drug Class
  • 3.7.2 Market Attractiveness Analysis By Route Of Administration
  • 3.7.3 Market Attractiveness Analysis By Distribution Channel
  • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

• 5.1. Impact Analysis of Covid-19 Outbreak
  • 5.1.1. Direct Impact on Production
  • 5.1.2. Supply Chain and Market Disruption
  • 5.1.3. Financial Impact on Firms and Financial Markets
• 5.2. COVID-19 Impact Analysis by Production, Import, Export and Demand
• 5.3. Market: Pre V/S Post COVID-19
• 5.4. Estimated Impact of the Coronavirus (COVID-19) Epidemic
• 5.5. COVID-19: Micro and Macro Factor Analysis

6 . GLOBAL VULVOVAGINAL CANDIDIASIS TREATMENT MARKET ANALYSIS BY DRUG CLASS

• 6.1 Overview by Drug Class
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Drug Class
• 6.4 Clotrimazole Historic and Forecast Sales by Regions
• 6.5 Nystatin Historic and Forecast Sales by Regions
• 6.6 Fluconazole Historic and Forecast Sales by Regions
• 6.7 Ketoconazole Historic and Forecast Sales by Regions
• 6.8 Terbinafine Historic and Forecast Sales by Regions
• 6.9 Terconazole Historic and Forecast Sales by Regions
• 6.10. Others Historic and Forecast Sales by Regions

7 . GLOBAL VULVOVAGINAL CANDIDIASIS TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

• 7.1 Overview by Route Of Administration
• 7.2 Historical and Forecast Data
• 7.3 Analysis by Route Of Administration
• 7.4 Oral Historic and Forecast Sales by Regions
• 7.5 Intravenous Historic and Forecast Sales by Regions
• 7.6 Topical Historic and Forecast Sales by Regions

8 . GLOBAL VULVOVAGINAL CANDIDIASIS TREATMENT MARKET SALES ANALYSIS BY DISTRIBUTION CHANNEL

• 8.1 Overview by Distribution Channel
• 8.2 Historical and Forecast Data
• 8.3 Analysis by Distribution Channel
• 8.4 Hospital Pharmacy Historic and Forecast Sales by Regions
• 8.5 Retail Pharmacy Historic and Forecast Sales by Regions
• 8.6 Online Pharmacy Historic and Forecast Sales by Regions

9 . GLOBAL VULVOVAGINAL CANDIDIASIS TREATMENT MARKET SALES ANALYSIS BY GEOGRAPHY

• 9.1. Regional Outlook Sales Analysis
• 9.2. Introduction Sales Analysis
• 9.3. North America Sales Analysis
  • 9.3.1. Overview, Historic and Forecast Sales Analysis
  • 9.3.2. North America By Segment Sales Analysis
  • 9.3.3. North America By Country Sales Analysis
  • 9.3.4. United State Sales Analysis
  • 9.3.5. Canada Sales Analysis
  • 9.3.6. Mexico Sales Analysis
• 9.4. Europe Sales Analysis
  • 9.4.1. Overview, Historic and Forecast Sales Analysis
  • 9.4.2. Europe by Segment Sales Analysis
  • 9.4.3. Europe by Country Sales Analysis
  • 9.4.4. United Kingdom Sales Analysis
  • 9.4.5. France Sales Analysis
  • 9.4.6. Germany Sales Analysis
  • 9.4.7. Italy Sales Analysis
  • 9.4.8. Russia Sales Analysis
  • 9.4.9. Rest Of Europe Sales Analysis
• 9.5. Asia Pacific Sales Analysis
  • 9.5.1. Overview, Historic and Forecast Sales Analysis
  • 9.5.2. Asia Pacific by Segment Sales Analysis
  • 9.5.3. Asia Pacific by Country Sales Analysis
  • 9.5.4. China Sales Analysis
  • 9.5.5. India Sales Analysis
  • 9.5.6. Japan Sales Analysis
  • 9.5.7. South Korea Sales Analysis
  • 9.5.8. Australia Sales Analysis
  • 9.5.9. Rest Of Asia Pacific Sales Analysis
• 9.6. Latin America Sales Analysis
  • 9.6.1. Overview, Historic and Forecast Sales Analysis
  • 9.6.2. Latin America by Segment Sales Analysis
  • 9.6.3. Latin America by Country Sales Analysis
  • 9.6.4. Brazil Sales Analysis
  • 9.6.5. Argentina Sales Analysis
  • 9.6.6. Peru Sales Analysis
  • 9.6.7. Chile Sales Analysis
  • 9.6.8. Rest of Latin America Sales Analysis
• 9.7. Middle East & Africa Sales Analysis
  • 9.7.1. Overview, Historic and Forecast Sales Analysis
  • 9.7.2. Middle East & Africa by Segment Sales Analysis
  • 9.7.3. Middle East & Africa by Country Sales Analysis
  • 9.7.4. Saudi Arabia Sales Analysis
  • 9.7.5. UAE Sales Analysis
  • 9.7.6. Israel Sales Analysis
  • 9.7.7. South Africa Sales Analysis
  • 9.7.8. Rest Of Middle East And Africa Sales Analysis

10 . COMPETITIVE LANDSCAPE OF THE VULVOVAGINAL CANDIDIASIS TREATMENT COMPANIES

• 10.1. Vulvovaginal Candidiasis Treatment Market Competition
• 10.2. Partnership/Collaboration/Agreement
• 10.3. Merger And Acquisitions
• 10.4. New Product Launch
• 10.5. Other Developments

11 . COMPANY PROFILES OF VULVOVAGINAL CANDIDIASIS TREATMENT INDUSTRY

• 11.1. Top 10 Company Share Analysis
• 11.2. Market Concentration Rate
• 11.3. Astellas Pharma Inc.
  • 11.3.1. Company Overview
  • 11.3.2. Company Revenue
  • 11.3.3. Products
  • 11.3.4. Recent Developments
• 11.4. Mycovia Pharmaceuticals Inc.
  • 11.4.1. Company Overview
  • 11.4.2. Company Revenue
  • 11.4.3. Products
  • 11.4.4. Recent Developments
• 11.5. Bayer AG.
  • 11.5.1. Company Overview
  • 11.5.2. Company Revenue
  • 11.5.3. Products
  • 11.5.4. Recent Developments
• 11.6. Basilea Pharmaceutica Ltd.
  • 11.6.1. Company Overview
  • 11.6.2. Company Revenue
  • 11.6.3. Products
  • 11.6.4. Recent Developments
• 11.7. Scynexis Inc.
  • 11.7.1. Company Overview
  • 11.7.2. Company Revenue
  • 11.7.3. Products
  • 11.7.4. Recent Developments
• 11.8. Grupo Ferrer Internacional S.A.
  • 11.8.1. Company Overview
  • 11.8.2. Company Revenue
  • 11.8.3. Products
  • 11.8.4. Recent Developments
• 11.9. Pfizer Inc.
  • 11.9.1. Company Overview
  • 11.9.2. Company Revenue
  • 11.9.3. Products
  • 11.9.4. Recent Developments
• 11.10. Cadila Pharmaceuticals
  • 11.10.1. Company Overview
  • 11.10.2. Company Revenue
  • 11.10.3. Products
  • 11.10.4. Recent Developments
• 11.11. Bristol-Myers Squibb Company
  • 11.11.1. Company Overview
  • 11.11.2. Company Revenue
  • 11.11.3. Products
  • 11.11.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

• Market Snapshot
• Drivers : Impact Analysis
• Restraints : Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• List of Potential Buyers
• COVID-19 Impact Analysis by Production, Import, Export and Demand
• Pre V/S Post COVID-19
• Estimated Impact Of The Coronavirus (Covid-19) Epidemic
• COVID-19: Micro and Macro Factor Analysis
• Analysis by Drug Class (USD MN)
• Clotrimazole Market Sales by Geography (USD MN)
• Nystatin Market Sales by Geography (USD MN)
• Fluconazole Market Sales by Geography (USD MN)
• Ketoconazole Market Sales by Geography (USD MN)
• Terbinafine Market Sales by Geography (USD MN)
• Terconazole Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Analysis Market by Route Of Administration (USD MN)
• Oral Market Sales by Geography (USD MN)
• Intravenous Market Sales by Geography (USD MN)
• Topical Market Sales by Geography (USD MN)
• Analysis by Distribution Channel (USD MN)
• Hospital Pharmacy Market Sales by Geography (USD MN)
• Retail Pharmacy Market Sales by Geography (USD MN)
• Online Pharmacy Market Sales by Geography (USD MN)
• Global Vulvovaginal Candidiasis Treatment Market Sales by Geography (USD MN)
• North America Market Analysis (USD MN)
• United State Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate by Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Vulvovaginal Candidiasis Treatment Report
• Market Research Process
• Market Research Methodology
• Global Vulvovaginal Candidiasis Treatment Market Size, by Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis by Drug Class
• Market Attractiveness Analysis by Route Of Administration
• Market Attractiveness Analysis by Distribution Channel
• Market Attractiveness Analysis by Region
• Value Chain Analysis
• Global Market Analysis by Drug Class (USD MN)
• Clotrimazole Market Sales by Geography (USD MN)
• Nystatin Market Sales by Geography (USD MN)
• Fluconazole Market Sales by Geography (USD MN)
• Ketoconazole Market Sales by Geography (USD MN)
• Terbinafine Market Sales by Geography (USD MN)
• Terconazole Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Global Market Analysis by Route Of Administration (USD MN)
• Oral Market Sales by Geography (USD MN)
• Intravenous Market Sales by Geography (USD MN)
• Topical Market Sales by Geography (USD MN)
• Global Market Analysis by Distribution Channel (USD MN)
• Hospital Pharmacy Market Sales by Geography (USD MN)
• Retail Pharmacy Market Sales by Geography (USD MN)
• Online Pharmacy Market Sales by Geography (USD MN)
• Global Market by Revenue
• North America Market by Revenue
• Europe Market by Revenue
• Asia Pacific Market by Revenue
• Latin America Market by Revenue
• Middle East & Africa Market by Revenue
• Recent Development in Industry
• Top Company Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.